Ocular Therapeutix, Inc. (OCUL)
Automate Your Wheel Strategy on OCUL
With Tiblio's Option Bot, you can configure your own wheel strategy including OCUL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OCUL
- Rev/Share 0.3517
- Book/Share 1.5699
- PB 5.1661
- Debt/Equity 0.2866
- CurrentRatio 10.2224
- ROIC -0.5513
- MktCap 1291923000.0
- FreeCF/Share -0.8762
- PFCF -8.7041
- PE -7.1289
- Debt/Assets 0.1878
- DivYield 0
- ROE -0.588
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | OCUL | William Blair | -- | Outperform | -- | -- | April 8, 2025 |
| Initiation | OCUL | RBC Capital Mkts | -- | Outperform | -- | $17 | March 18, 2025 |
| Initiation | OCUL | Needham | -- | Buy | -- | $15 | March 11, 2025 |
| Initiation | OCUL | Scotiabank | -- | Sector Outperform | -- | -- | Oct. 16, 2024 |
News
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago.
Read More
Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential
Published: March 06, 2025 by: Seeking Alpha
Sentiment: Positive
Ocular Therapeutix focuses on Axpaxli, a long-acting wet AMD therapy administered every 6-12 months. Dextenza currently drives revenues, but Axpaxli is expected to unlock long-term growth. Ocular has two important Phase 3 trials (SOL-1 and SOL-R), which are key catalysts this year, with data expected by early 2026.
Read More
Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Negative
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.28 per share a year ago.
Read More
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
BEDFORD, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss recent business progress and financial results for the fourth quarter and full year ended December 31, 2024.
Read More
About Ocular Therapeutix, Inc. (OCUL)
- IPO Date 2014-07-25
- Website https://www.ocutx.com
- Industry Biotechnology
- CEO Dr. Pravin U. Dugel M.D.
- Employees 274